FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application for Phase 2 Study of oral TNF- inhibitor MYMD-1 in Rheumatoid Arthritis
MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
BALTIMORE, August 14, 2023 MyMD Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that the U.S. Food and Drug Administration has accepted the Companys Investigational New Drug Application to evaluate the safety, efficacy, pharmacodynamics and pharmacokinetics of oral TNF- inhibitor MYMD-1 in patients wi
Read at finance.yahoo.com
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
UBX | Unity Biotechnology | 4.17 | ||||
RXRX | Recursion Pharmaceuticals | 3.58 | ||||
GOVX | GeoVax Labs | 2.26 | ||||
DSGN | Design Therapeutics | 2.25 | ||||
BOLT | Bolt Biotherapeutics | 2.00 | ||||
KZR | Kezar Life | 1.86 | ||||
NVCT | Nuvectis Pharma | 1.53 | ||||
XBIO | Xenetic Biosciences | 1.47 | ||||
REPL | Replimune | 1.30 | ||||
LYRA | Lyra Therapeutics | 1.18 | ||||
AVIR | Atea Pharmaceuticals | 0.31 | ||||
PASG | Passage Bio | 0.15 | ||||
SRZN | Surrozen | 0.08 | ||||
NBY | NovaBay Pharmaceuticals | 0 | ||||
LGND | Ligand Pharmaceuticals | 0.37 | ||||
KRON | Kronos Bio | 1.04 | ||||
LYEL | Lyell Immunopharma | 1.61 | ||||
ORIC | Oric Pharmaceuticals | 1.68 | ||||
GOSS | Gossamer Bio | 2.33 | ||||
KROS | Keros Therapeutics | 2.39 | ||||
REVB | Revelation Biosciences | 3.23 | ||||
LRMR | Larimar Therapeutics | 4.55 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |